诺思格1月26日获融资买入2310.44万元,融资余额1.19亿元

Group 1 - The core viewpoint of the news is that Norsg (Beijing) Pharmaceutical Technology Co., Ltd. experienced a decline in stock price and significant trading activity, indicating high investor interest and potential volatility in the market [1][2]. Group 2 - On January 26, Norsg's stock price fell by 3.71%, with a trading volume of 214 million yuan. The financing buy-in amount was 23.10 million yuan, while the financing repayment was 22.31 million yuan, resulting in a net financing buy of 797,000 yuan [1]. - As of January 26, the total balance of margin trading for Norsg was 119 million yuan, accounting for 2.92% of its circulating market value, which is above the 90th percentile level over the past year [1]. - In terms of securities lending, on January 26, Norsg repaid 800 shares and sold 600 shares, with a selling amount of 42,500 yuan. The remaining securities lending balance was 3,800 shares, with a total balance of 269,300 yuan, also above the 90th percentile level over the past year [1]. Group 3 - Norsg was established on August 22, 2008, and went public on August 2, 2022. Its main business includes clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2]. - The revenue composition of Norsg's main business is as follows: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2]. - As of September 30, 2025, Norsg achieved an operating income of 607 million yuan, representing a year-on-year growth of 8.09%, and a net profit attributable to shareholders of 95.57 million yuan, with a year-on-year increase of 13.21% [2]. Group 4 - Since its A-share listing, Norsg has distributed a total of 49.50 million yuan in dividends [3]. - As of September 30, 2025, the number of shareholders of Norsg was 8,734, a decrease of 16.18% from the previous period, while the average circulating shares per person increased by 19.30% to 6,545 shares [2][3]. - Among the top ten circulating shareholders, Nuoan Pioneer Mixed A (320003) ranked as the sixth largest shareholder with 1.68 million shares, while Hong Kong Central Clearing Limited ranked as the tenth largest shareholder with 690,400 shares, a decrease of 138,500 shares from the previous period [3].

R&G PharmaStudies -诺思格1月26日获融资买入2310.44万元,融资余额1.19亿元 - Reportify